Group items tagged

The Science and Technology Centers (STC): Integrative Partnerships program supports exceptionally innovative, complex research and education projects that require large-scale, long-term awards. STCs focus on creating new scientific paradigms, establishing entirely new scientific disciplines and developing transformative technologies which have the potential for broad scientific or societal impact. STCs conduct world-class research through partnerships among institutions of higher education, national laboratories, industrial organizations, other public or private entities, and via international collaborations, as appropriate. They provide a means to undertake potentially groundbreaking investigations at the interfaces of disciplines and/or highly innovative approaches within disciplines. STCs may involve any area of science and engineering that NSF supports. STC investments support the NSF vision of creating and exploiting new concepts in science and engineering and providing global leadership in research and education.

The Foundation Fighting Blindness, the world's leading organization searching for treatments and cures for inherited retinal diseases, is launching a new Translational Research Acceleration Program (TRAP) to help advance vision-saving research toward the clinical usage. The Foundation is accepting applications for retinal degeneration treatment approaches, including but not limited to: genetic therapies, regenerative treatments, and novel medical therapies. There are a variety of TRAP grant mechanisms that can provide up to $1.5 million in funding over three years.

The FY15/16 VRP Technology/Therapeutic Development Award (TTDA) is a mission-driven award intended to provide support for the translation of promising preclinical findings into products for clinical applications, including detection, diagnosis, treatment, or quality of life, in at least one of the FY15/16 VRP TTDA Capability Gaps. Products in development should be responsive to the health care needs of military Service members, Veterans, and other individuals living with visual dysfunction. 

The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research.

The FY18 VRP IIRA is intended to support studies that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma. Research projects may focus on any phase of research (e.g., basic, translational, applied, clinical, observational), excluding clinical trials. The research idea or solution should be innovative, novel, or a significant advancement over existing ideas or solutions, as applicable.

The FY18 VRP FTTSA is intended to support a highly collaborative and translational team initiative that will fundamentally advance the understanding and treatment of eye injury and/or visual dysfunction that result from a military-relevant traumatic event (e.g., blast, blunt, thermal, chemical, biological, directed energy, ionizing radiation).

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for short-term, proof-of-principle research projects that will provide preliminary data for a future FOA aimed at the development of new models that emulate human visual system anatomy, physiology and disease processes. The model system might involve specific defects generated by transgenic gene insertion and/or deletion, gene editing, chemical/physical means, and/or other approaches to emulate characteristics of human disease or create defects amenable to cell-replacement and/or regenerative therapy. Using non-human primates or other cone-dominant species that are more representative of the anatomy and physiology of the human retina are highly encouraged. Other biological models are acceptable provided they meet the overall objectives of the FOA.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for short-term, proof-of-principle research projects that will provide preliminary data for a future FOA aimed at the development of new models that emulate human visual system anatomy, physiology and disease processes.

The FY19 VRP Translational Research Award is intended to support translational research that moves promising discoveries into clinical applications that will advance the prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military-relevant trauma. Successful applications to the FY19 VRP TRA should establish a clear path to transform a discovery into new drugs, devices, or clinical practice guidelines that are ready for definitive testing in clinical trials. It is expected that an Investigational New Drug (IND)/Investigational Device Exemption (IDE) application will be submitted during or by the end of the period of performance. Applicants are strongly encouraged to include at least one collaborator with expertise in the U.S. Food and Drug Administration (FDA) regulatory approval process on the investigative team.

The FY19 VRP IIRA is intended to support studies that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma. Research projects may focus on any phase of research (e.g., basic, translational, applied, clinical, observational), excluding clinical trials. The research idea or solution should be innovative or novel, or a significant advancement over existing ideas or solutions, as applicable.